Phase II study of bortezomib-melphalan-prednisolone induction therapy followed by lenalidomide-plus-dexamethasone consolidation and lenalidomide maintenance for newly diagnosed patients with multiple myeloma ineligible for stem cell transplantation.
Latest Information Update: 02 Jun 2020
At a glance
- Drugs Lenalidomide (Primary) ; Bortezomib; Bortezomib; Dexamethasone; Melphalan; Prednisolone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms CANDLE
- 01 May 2020 Results published in the Annals of Hematology
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 08 Dec 2015 Interim results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology